EichorEICHOR
Location: Wilson Synced from ClinicalTrials.gov · August 07, 2026

Clinical studies recruiting near Wilson

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in
Phase 3 · Carolina Cancer Research Center · Pfizer · NCT06758401A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advance
Phase 3 · Research Site · AstraZeneca · NCT06692738A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Phase 1 · Carolina Cancer Research Center · Pliant Therapeutics, Inc. · NCT06270706BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
Phase 3 · Carolina Cancer Research Center · BeOne Medicines · NCT07492641A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monother
Phase 1/Phase 2 · GSK Investigational Site · GlaxoSmithKline · NCT05714839A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurre
Phase 3 · Carolina Cancer Research Center · Janssen Research & Development, LLC · NCT07276399A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Phase 1/Phase 2 · Regional Medical Oncology Center · DualityBio Inc. · NCT05150691A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
Phase 2 · GSK Investigational Site · GlaxoSmithKline · NCT06920043Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head
Phase 2 · ECOG-ACRIN Cancer Research Group · NCT02734537Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Phase 3 · Regional Medical Oncology NC · Novartis Pharmaceuticals · NCT05827081Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-sm
Phase 3 · Carolina Cancer Research Center · Daiichi Sankyo · NCT06899126BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
Phase 2 · Carolina Cancer Research Center · SCRI Development Innovations, LLC · NCT06773910An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Pat
Phase 4 · Research Site · AstraZeneca · NCT07357597Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Phase 3 · Regional Medical Oncology Center_Wlson · BriaCell Therapeutics Corporation · NCT06072612Social Worker-led Mindfulness-based Intervention for Older People
NA · The University of Hong Kong · NCT06528132Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)
Phase 1/Phase 2 · Regional Oncology Center · Starton Therapeutics, Inc · NCT06087653A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer
Phase 3 · Carolina Cancer Research Center · Eli Lilly and Company · NCT07174336DESTINY-PANTUMOUR04
Phase N/A · Research Site · AstraZeneca · NCT07124000A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, f
Phase 2 · Regional Medical Oncology Center · Janssen Research & Development, LLC · NCT06667076Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adu
Phase 3 · Carolina Cancer Research Center · Pfizer · NCT07222566A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA
Phase 3 · Hoffmann-La Roche · NCT05797610Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Phase 2 · Alliance for Clinical Trials in Oncology · NCT02523014Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Resp
Phase 3 · Regional Medical Oncology Center · Kartos Therapeutics, Inc. · NCT06479135
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.